Finalist
Novartis – Inclisiran
Summary of work
With the backdrop of COVID-19, a cluttered health news agenda and limited public trust in pharma, Hanover supported the launch of the Novartis cholesterol-lowering medicine inclisiran (Leqvio®) – a new, first-in-class drug to help lower LDL cholesterol; and in tandem, announce its role in a groundbreaking new collaborative industry and NHS approach to adoption of innovative medicines within a primary care setting.
Developed in partnership with NHS England and Improvement (NHSE&I), the National Institute for Health and Care Excellence (NICE) and others the inaugural NHS ‘Population Health Agreement’ was an important world-first partnership. It was therefore imperative the public, healthcare professionals (HCPs) and media understood the impact it would have on the future of heart health management in England and for the patients who could receive the new drug.
Judges’ comments
This entry illustrated a solid partnership between Novartis and the NHS, using credible voices to lead the story and clear infographics in the media explaining cardiovascular disease and cholesterol. The judges were impressed with the overall media coverage made by the campaign.
